ZDA
BBIO icon

Zweig-DiMenna Associates’s BridgeBio Pharma BBIO Stock Holding History

Zweig-DiMenna Associates’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-115,515
Closed -$7.04M – 169
2021
Q2 		$7.04M Buy
+115,515
New +$6.6M 0.42% 87

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Zweig-DiMenna Associates's BBIO Position: Q3 2021 in Review

Zweig-DiMenna Associates sold out of BridgeBio Pharma (BBIO) in Q3 2021, closing a stake of 115,515 shares — an estimated $7.04M sold.

Zweig-DiMenna Associates first reported a position in BBIO in Q2 2021 and held it in 1 quarter. The position peaked at $7.04M in Q2 2021. 210 funds tracked by Wall St. Rank hold BBIO as of Q3 2021.

  • Zweig-DiMenna Associates reported no remaining BridgeBio Pharma position as of Q3 2021 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 115,515 BridgeBio Pharma shares in Q3 2021, an estimated $7.04M.
  • Zweig-DiMenna Associates first reported a position in BridgeBio Pharma in Q2 2021 and held it in 1 quarter.
  • Zweig-DiMenna Associates's BridgeBio Pharma position peaked at $7.04M in Q2 2021.
  • 210 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2021.

Based on Zweig-DiMenna Associates's 13F filing for Q3 2021, filed 25 Oct 2021.